Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
about
Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseasesHepatocellular carcinoma: Review of disease and tumor biomarkersPrognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospectsIdentification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndromeLong-term differential changes in mouse intestinal metabolomics after γ and heavy ion radiation exposureMetabolic characterization of the early stage of hepatic fibrosis in rat using GC-TOF/MS and multivariate data analyses.Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis.Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancerThe metabolomic window into hepatobiliary disease.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.MALDI imaging MS reveals candidate lipid markers of polycystic kidney diseaseDetection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian CohortMetabolomic profiles of hepatocellular carcinoma in a European prospective cohort.LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma.Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients.Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinomaTissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma.Review of mass spectrometry-based metabolomics in cancer research.Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosisSerum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients.Metabonomics Research Progress on Liver Diseases.Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.Metabolomics for tumor marker discovery and identification based on chromatography-mass spectrometry.Oncometabolomics in cancer research.A rough guide to metabolite identification using high resolution liquid chromatography mass spectrometry in metabolomic profiling in metazoansAdvanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma.Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.Disease monitoring of hepatocellular carcinoma through metabolomics.Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma.Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and 1H NMR based metabolomics.Detecting serum and urine metabolic profile changes of CCl4-liver fibrosis in rats at 12 weeks based on gas chromatography-mass spectrometry.Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach.Prioritization of putative metabolite identifications in LC-MS/MS experiments using a computational pipeline.Gamma-irradiated β-glucan modulates signaling molecular targets of hepatocellular carcinoma in rats.
P2860
Q26741550-36A2A299-6FD6-443F-A2D6-7C63E47F9329Q26750796-BAA29C14-4747-4045-9A0E-2E07C9A8D712Q27021265-0BE66DAF-1D90-4750-898B-2D7C60F710FBQ28538533-A96B1BEC-541E-4520-99E8-B713220FE1C9Q28539199-03E75809-6AEE-4C31-B9F4-B77BACC32C52Q31143019-B58E42AE-BDE4-4E91-B176-C3667A192CEAQ31148475-611D6965-E635-4D4C-B4F9-A623F88534F9Q33843741-419496C9-0D08-49E7-AC81-4B984D2FEB63Q33893457-3CE7CFDF-B35E-4F37-8234-7983E9D8A6D4Q34214476-8B657C76-BA9B-46EE-B373-6204A0C3C2F5Q34451211-112CC712-2341-4523-A17D-CE37C70C54D4Q34818710-2116A350-A526-483A-804E-96DF16C5A737Q35007172-5EEFF838-6450-47FE-BF38-571532A858E8Q35648370-232E221B-0B29-4D3C-8AA1-1F50672FDAACQ35785514-9FE8D33E-84B6-4330-BE31-BCE29FB94E04Q35812050-8B750530-057E-4327-AEAE-214B1F4F3709Q36197829-96778B09-3D52-497E-88E5-6A53441B94EAQ36360941-A1CBC8F6-1CF2-4439-9040-69CEFA33AC7DQ36932065-5BF8C54F-AE31-4B45-87C4-33270EDBCB7FQ36961679-43EBEC0B-2A27-4CB8-9EE9-97E0BEB1F2E3Q37109693-B64DE80E-4574-4516-BDA4-08B168DD020CQ37218954-E61A7291-6948-4357-818E-A1B417BE8D8EQ37550758-349CD280-3FD5-43AB-B1ED-9720A75641C2Q37625766-D7193EA1-9BE7-4BE2-93F4-234F810D9E01Q37642807-F351588C-2683-439F-9AFB-FAA0CE417493Q37683642-E7A281F8-6DB2-42BC-8702-9F628F25E623Q38059646-6F9239CD-D33E-4A81-8A8A-81DCD70584A2Q38103592-3C09560E-F357-4287-B131-1BFB971D65AEQ38132912-39360BF7-9226-4F1B-93C0-1B6D455F3B55Q38201037-3380AE97-6159-4342-9D5A-C1E06418AED2Q38217062-CF357A04-45A2-4E55-A95C-624972E83B93Q38397273-93978065-B269-4CAB-B91F-846F80D5E0D1Q38450711-231FF514-C697-4499-90DA-BD0CD29A7D6FQ38768256-15660B4D-D340-4F1C-9A29-7D858F8A084BQ38983451-5E45EDA6-2406-4068-98F3-0BD89622060FQ39453822-9846B62A-E587-4CDE-825B-646829A6D110Q40092504-D6CE4D04-80EA-4E58-90E8-78AF985EAEC7Q41200837-DDF235E6-E5A0-420D-8B0E-6189DA7AA389Q43079293-2CA49BB9-033D-4DC9-A7AA-C64CBFA104B3Q46659792-A84C9AB7-B738-43CB-9875-B42139CDEF8A
P2860
Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Utilization of metabolomics to ...... patients with liver cirrhosis
@ast
Utilization of metabolomics to ...... patients with liver cirrhosis
@en
type
label
Utilization of metabolomics to ...... patients with liver cirrhosis
@ast
Utilization of metabolomics to ...... patients with liver cirrhosis
@en
prefLabel
Utilization of metabolomics to ...... patients with liver cirrhosis
@ast
Utilization of metabolomics to ...... patients with liver cirrhosis
@en
P2093
P2860
P921
P1476
Utilization of metabolomics to ...... patients with liver cirrhosis
@en
P2093
Amrita K Cheema
Cristina Di Poto
Habtom W Ressom
Jinlian Wang
Jun Feng Xiao
Kirti Shetty
Leepika Tuli
Mahlet G Tadesse
Mohammad R Nezami Ranjbar
P2860
P304
P356
10.1016/J.ACA.2012.07.013
P577
2012-07-20T00:00:00Z